The Latest Breaking News from FDA

The Biden administration is invoking the Defense Production Act to increase baby formula production, requiring suppliers to prioritize giv

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Food and Drug Administration has reached an agreement with Abbott Laboratories to resume production at the company’s Sturgis, Michigan, facility. The announcement gives hope of relief for the three-fourths of American parents who rely on infant formula, and have struggled to find the product in recent weeks.

Bad policy makes people vulnerable, and the current baby formula shortage is just the latest example. The immediate cause of the shortage was contamination in a Michigan factory, which might not resume production until June. But the underlying cause is a slew of bad policies that make the market less…

Biden is also authorizing the Defense Department to use commercial aircraft to fly formula supplies that meet federal standards from overseas to the U.S.

Europe's Nestlé SA (OTC: NSRGF) is ramping up hypoallergenic (HA) baby formula production to alleviate the shortage in U.S. supermarkets.

Aldeyra Therapeutics Inc (NASDAQ:ALDX) reported a post-hoc analysis from the completed Phase 3 TRANQUILITY dry eye chamber trial of reproxalap for dry eye disease. Using computer-automated grading of digital photography from the trial demonstrated statistical significance in favor of reproxalap over the vehicle for the primary endpoint of reducing ocular redness.  As previously…

This year, at Davos some of the world’s most prominent psychedelic industry leaders and researchers will attend a satellite event that will run parallel to the World Economic Forum.

Bexson Biomedical recently signed a deal with the Stevanato Group to develop a subcutaneous delivery system of ketamine.